Hipertensión intracraneal secundaria a trombosis de senos venosos / Intracranial hypertension secondary to a venous sinus thrombosis

No disponible

Aceite de silicona pesado (Densiron ® 68) en vitreorretinopatía proliferativa: 4 años de experiencia / Heavy silicone oil (Densiron ® 68) in proliferative vitreoretinopathy: 4 years of experience

Método: Se estudiaron los antecedentes de 10 pacientes (rango de edad: 27-74 años), los cuales, a pesar de una media de 2,8 intervenciones previas, presentaban de nuevo desprendimiento de retina (DR) y vitreorretinopatía proliferativa (VRP). En todos ellos se optó por realizar retinotomía quirúrgica e implantación de Densiron® y valoramos su evolución con un seguimiento de 12 meses. Resultados: El tiempo medio de Densiron® hasta su retirada fue de 4 meses. Tres pacientes (30%) presentaron nuevo DR. El desarrollo de cataratas fue la complicación principal. No encontramos relación entre los redesprendimientos y la duración del tamponamiento, enfermedad de base o tiempo de evolución del DR. Densiron® puede ser una buena opción en casos de DR recidivante en los que el tratamiento previo con cerclaje, gas o aceites de silicona de 1.000/5.000 cts resulte insuficiente (AU)

Method: Prospective observational study including 10 patients (age range: 27-74 years) with recurrent retinal detachment (RD) and proliferative vitreoretinopathy (PVR) and 2.8 mean unsatisfactory previous surgeries. Densiron® was injected in all patients, with surgical retinectomy being required in 70% of them. Minimum follow-up time was 12 months. Results: The mean length of time before Densiron® withdrawal was 4 months. Three patients (30%) presented with a new RD. The main complication detected was cataract development. No relationship was found between re-detachments and tamponade time, baseline disease or RD evolution time. Densiron® may be a good option in cases of recurrent RD in which previous treatment with scleral buckle, gas and/or 1,000/5,000 silicone oils has proven to be unsatisfactory (AU)

Síndrome de aumento agudo idiopático de mancha ciega asociado a neovascularización coroidea / Acute idiopathic blind spot enlargement syndrome associated with choroidal neovascularization

Caso clínico: Mujer de 17 años que consulta por fotopsias y escotoma en OI, con antecedente de neovascularización coroidea contralateral. La exploración sugiere un síndrome de aumento agudo idiopático de mancha ciega. La evolución sin tratamiento es favorable, con disminución del escotoma y sin empeoramiento de su agudeza visual. Discusión: El síndrome de aumento agudo idiopático de mancha ciega es un síndrome raro y benigno, propio de mujeres jóvenes. Se debe hacer un diagnóstico diferencial con el síndrome de puntos blancos evanescentes y la retinopatía aguda zonal externa oculta. Tras revisar la bibliografía, no hemos hallado ningún caso descrito previamente en asociación con la neovascularización coroidea, hecho que nos obliga a cuestionarnos su benignidad (AU)

Clinical case: A 17 year old female consulting due to photopsia and a sudden loss of visual field in left eye (OS), with previous contralateral choroidal neovascularization. The examination suggested an acute idiopathic blind spot syndrome. The progress without treatment was favorable, with a reduction in the scotoma and without a worsening of her visual acuity. Discussion: This case report is about an unusual and benign syndrome, typical of young women. Differential diagnosis must be made between the evanescent white dot syndrome and the acute zonal occult outer retinopathy. To our knowledge, this is the first published case associated with choroidal neovascularization, a fact that leads us to question its benignancy (AU)

[Heavy silicone oil (Densiron® 68) in proliferative vitreoretinopathy: 4 years of experience]. / Aceite de silicona pesado (Densiron(®) 68) en vitreorretinopatía proliferativa: 4 años de experiencia.

METHOD: Prospective observational study including 10 patients (age range: 27-74 years) with recurrent retinal detachment (RD) and proliferative vitreoretinopathy (PVR) and 2.8 mean unsatisfactory previous surgeries. Densiron® was injected in all patients, with surgical retinectomy being required in 70% of them. Minimum follow-up time was 12 months. RESULTS: The mean length of time before Densiron® withdrawal was 4 months. Three patients (30%) presented with a new RD. The main complication detected was cataract development. No relationship was found between re-detachments and tamponade time, baseline disease or RD evolution time. Densiron® may be a good option in cases of recurrent RD in which previous treatment with scleral buckle, gas and/or 1,000/5,000 silicone oils has proven to be unsatisfactory.

[Acute idiopathic blind spot enlargement syndrome associated with choroidal neovascularization]. / Síndrome de aumento agudo idiopático de mancha ciega asociado a neovascularización coroidea.

CLINICAL CASE: A 17 year old female consulting due to photopsia and a sudden loss of visual field in left eye (OS), with previous contralateral choroidal neovascularization. The examination suggested an acute idiopathic blind spot syndrome. The progress without treatment was favorable, with a reduction in the scotoma and without a worsening of her visual acuity. DISCUSSION: This case report is about an unusual and benign syndrome, typical of young women. Differential diagnosis must be made between the evanescent white dot syndrome and the acute zonal occult outer retinopathy. To our knowledge, this is the first published case associated with choroidal neovascularization, a fact that leads us to question its benignancy.